Nonfatal myocardial infarction occurred in 2.3% of patients treated with oral semaglutide and 1.9% treated with placebo (HR 1.18, 95% CI 0.731.90), nonfatal stroke occurred in 0.8% versus 1.0% treated with placebo (HR 0.74, 95% CI 0.351.57), and death from cardiovascular causes occurred in 0.9% versus 1.9% treated with placebo (HR 0.51, 95% CI 0.310.84)
If anything feels off, we adjust your plan
Tirzepatide (Mounjaro and Zepbound), a GLP-1 and GIP receptor agonist, has recently gained significant popularity for its weight loss benefits
Automotive OEMs, Tier-1 suppliers, and technology companies are deploying simulators as a core component of their development pipeline, reducing costs, accelerating iteration cycles, and improving system safety